"The Trump administration is putting patients first by increasing transparency, lowering costs and expanding access through TrumpRx," HHS Secretary Robert F. Kennedy Jr. said.

Looking ahead to this year, CFO Mike Hart expects revenues to range between $76.5 billion and $80 billion.

"Brokers are being asked to guide clients through rising regulatory pressure, economic uncertainty and AI adoption all at once," said Jura Slattery, chief customer officer at isolved.

Getting clearer cost information before picking up a prescription would make managing medications easier for 36% of patients.

This represents a 4.5% gain from the second quarter and accounting for more than one-third of all household financial assets.

A number of factors can contribute to drug shortages, including supply chain disruptions, a limited number of manufacturers, regulatory burdens, small profit margins, natural disasters and unforeseen surges in demand for certain drugs.

"In 2025, shadow AI surged across health care organizations as staff across all aspects of care sought ways to improve efficiency amid persistent burnout, staffing shortages and other factors," said Alex Tyrell, senior vice president and chief technology officer at Wolters Kluwer.

This was the first time the company had placed a dollar figure on the potential impact of its decision to end rebates.